- Home
- PAVS vs AGEN Comparison
PAVS vs AGEN Comparison
Compare PAVS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVS
- AGEN
- Stock Information
- Founded
- PAVS 2004
- AGEN 1994
- Country
- PAVS United States
- AGEN United States
- Employees
- PAVS N/A
- AGEN N/A
- Industry
- PAVS Medicinal Chemicals and Botanical Products
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAVS Health Care
- AGEN Health Care
- Exchange
- PAVS Nasdaq
- AGEN Nasdaq
- Market Cap
- PAVS 88.9M
- AGEN 96.2M
- IPO Year
- PAVS 2019
- AGEN 2000
- Fundamental
- Price
- PAVS $1.34
- AGEN $3.48
- Analyst Decision
- PAVS
- AGEN Buy
- Analyst Count
- PAVS 0
- AGEN 3
- Target Price
- PAVS N/A
- AGEN $10.50
- AVG Volume (30 Days)
- PAVS 103.9K
- AGEN 419.4K
- Earning Date
- PAVS 08-01-2024
- AGEN 03-13-2025
- Dividend Yield
- PAVS N/A
- AGEN N/A
- EPS Growth
- PAVS N/A
- AGEN N/A
- EPS
- PAVS N/A
- AGEN N/A
- Revenue
- PAVS $6,544,819.00
- AGEN $160,427,000.00
- Revenue This Year
- PAVS N/A
- AGEN N/A
- Revenue Next Year
- PAVS N/A
- AGEN $36.13
- P/E Ratio
- PAVS N/A
- AGEN N/A
- Revenue Growth
- PAVS N/A
- AGEN 59.00
- 52 Week Low
- PAVS $0.32
- AGEN $2.50
- 52 Week High
- PAVS $2.81
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- PAVS 62.00
- AGEN 58.60
- Support Level
- PAVS $1.27
- AGEN $3.08
- Resistance Level
- PAVS $1.39
- AGEN $3.29
- Average True Range (ATR)
- PAVS 0.09
- AGEN 0.26
- MACD
- PAVS -0.01
- AGEN 0.05
- Stochastic Oscillator
- PAVS 48.00
- AGEN 80.36
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).